{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:17:28Z","timestamp":1781191048107,"version":"3.54.1"},"reference-count":67,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T00:00:00Z","timestamp":1495152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ontario Preclinical Imaging Consortium (OPIC)","award":["RE03-51"],"award-info":[{"award-number":["RE03-51"]}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-80203 & MOP-287694"],"award-info":[{"award-number":["MOP-80203 & MOP-287694"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Molecular Function and Imaging Heart and Stroke Foundation of Ontario Program","award":["PRG6242"],"award-info":[{"award-number":["PRG6242"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0177451","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T19:37:28Z","timestamp":1495741048000},"page":"e0177451","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Treatment with enalapril and not diltiazem ameliorated progression of chronic kidney disease in rats, and normalized renal AT1 receptor expression as measured with PET imaging"],"prefix":"10.1371","volume":"12","author":[{"given":"Basma","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob A.","family":"deKemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Croteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayebeh","family":"Hadizad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob S.","family":"Beanlands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean N.","family":"DaSilva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,5,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1503\/cmaj.080351","article-title":"Guidelines for the management of chronic kidney disease","volume":"179","author":"A Levin","year":"2008","journal-title":"CMAJ"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"E417","DOI":"10.1503\/cmaj.120833","article-title":"Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey","volume":"185","author":"P Arora","year":"2013","journal-title":"CMAJ"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa0910975","article-title":"Intensive blood-pressure control in hypertensive chronic kidney disease","volume":"363","author":"LJ Appel","year":"2010","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1681\/ASN.2004110919","article-title":"Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations","volume":"16","author":"MA Pohl","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","article-title":"Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria","volume":"110","author":"FW Asselbergs","year":"2004","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1524-6175.2004.4471.x","article-title":"Management of hypertensive chronic kidney disease: role of calcium channel blockers","volume":"7","author":"RD Toto","year":"2005","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/hr.2010.67","article-title":"Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy","volume":"33","author":"V Sukumaran","year":"2010","journal-title":"Hypertens Res"},{"issue":"Suppl 1","key":"ref8","first-page":"S81","article-title":"Cardiovascular parameters in rat model of chronic renal failure induced by subtotal nephrectomy","volume":"59","author":"J Sviglerova","year":"2010","journal-title":"Physiol Res \/ Academia Scientiarum Bohemoslovaca"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11886-008-0071-8","article-title":"Potential risks of calcium channel blockers in chronic kidney disease","volume":"10","author":"KA Griffin","year":"2008","journal-title":"Curr Cardiol Rep"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis","volume":"139","author":"TH Jafar","year":"2003","journal-title":"Ann Intern Med"},{"key":"ref11","first-page":"655","article-title":"Targeting the renin angiotensin system for remission\/regression of chronic kidney disease","volume":"25","author":"D Macconi","year":"2010","journal-title":"Histol Histopathol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"B Brenner","year":"2001","journal-title":"N Eng J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"E Lewis","year":"2001","journal-title":"N Eng J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1046\/j.1523-1755.2001.00790.x","article-title":"Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients","volume":"60","author":"HH Parving","year":"2001","journal-title":"Kidney int"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"HH Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","article-title":"Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)","volume":"356","author":"MJ Brown","year":"2000","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"A Officers","year":"2002","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"JT Wright Jr.","year":"2002","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0197-2456(98)00013-0","article-title":"Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial","volume":"19","author":"HR Black","year":"1998","journal-title":"Control Clin Trials"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","article-title":"Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study","volume":"356","author":"L Hansson","year":"2000","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/01.HYP.0000184541.24700.c7","article-title":"Calcium antagonists: effects on cardio-renal risk in hypertensive patients","volume":"46","author":"S Nathan","year":"2005","journal-title":"Hypertension"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/1568016052773261","article-title":"Influence of chronic kidney disease development and renin-angiotensin system inhibition on cardiovascular prognosis","volume":"3","author":"J Segura","year":"2005","journal-title":"Curr Med Chem Cardiovasc Hematol Agents"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pharmthera.2010.05.006","article-title":"Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives","volume":"128","author":"JM Lopez-Novoa","year":"2010","journal-title":"Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/ncpneph0299","article-title":"The benefits of renin-angiotensin blockade in hypertension are dependent on blood-pressure lowering","volume":"2","author":"AK Bidani","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1016\/j.bmc.2014.06.011","article-title":"Synthesis and evaluation of the novel 2-[(1)(8)F]fluoro-3-propoxy-triazole-pyridine-substituted losartan for imaging AT(1) receptors","volume":"22","author":"N Arksey","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/jlcr.1917","article-title":"[11C]Methyl-losartan as a potential ligand for PET imaging angiotensin II AT1 receptors","volume":"54","author":"T Hadizad","year":"2011","journal-title":"J Label Compd Radiopharm"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"7971","DOI":"10.1016\/j.bmc.2009.10.016","article-title":"Novel O-[(11)C]methylated derivatives of candesartan as angiotensin II AT(1) receptor imaging ligands: radiosynthesis and ex vivo evaluation in rats","volume":"17","author":"T Hadizad","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.nucmedbio.2015.06.012","article-title":"Evaluation of [(11)C]methyl-losartan and [(11)C]methyl-EXP3174 for PET imaging of renal AT1receptor in rats","volume":"42","author":"B Ismail","year":"2015","journal-title":"Nucl Med Biol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.nucmedbio.2012.10.013","article-title":"Analysis of [11C]methyl-candesartan kinetics in the rat kidney for the assessment of angiotensin II type 1 receptor density in vivo with PET","volume":"40","author":"M Lortie","year":"2013","journal-title":"Nucl Med Biol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13550-016-0209-4","article-title":"Decreased renal AT1 receptor binding in rats after subtotal nephrectomy: PET study with [(18)F]FPyKYNE-losartan","volume":"6","author":"B Ismail","year":"2016","journal-title":"EJNMMI Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"F1146","DOI":"10.1152\/ajprenal.90732.2008","article-title":"Curcumin ameliorates renal failure in 5\/6 nephrectomized rats: role of inflammation","volume":"296","author":"SS Ghosh","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3317\/jraas.2006.041","article-title":"Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5\/6 nephrectomy","volume":"7","author":"WA Windt","year":"2006","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/ndt\/8.6.501","article-title":"Effect of timing of antihypertensive therapy on glomerular injury: comparison between captopril and diltiazem","volume":"8","author":"E Podjarny","year":"1993","journal-title":"Nephrol Dial Transplant"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/ndt\/gfh383","article-title":"Effect of chronic tetrahydrobiopterin supplementation on blood pressure and proteinuria in 5\/6 nephrectomized rats","volume":"19","author":"E Podjarny","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"F1523","DOI":"10.1152\/ajprenal.00426.2009","article-title":"Effect of ACE2 and angiotensin-(1\u20137) in a mouse model of early chronic kidney disease","volume":"298","author":"M Dilauro","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1124\/jpet.107.123638","article-title":"Intra-renal angiotensin II\/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction","volume":"323","author":"ND Vaziri","year":"2007","journal-title":"J of Pharmacol Exp Ther"},{"key":"ref38","article-title":"Characterization of [18F]FPyKYNE-losartan for Imaging AT1 Receptors","author":"M Hachem","year":"2015","journal-title":"J Nucl Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1471-4159.1987.tb13129.x","article-title":"Kinetic modeling of receptor-ligand binding applied to positron emission tomographic studies with neuroleptic tracers","volume":"48","author":"J Logan","year":"1987","journal-title":"J Neurochem"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s12350-010-9256-9","article-title":"Quantification of myocardial blood flow and flow reserve: Technical aspects","volume":"17","author":"R Klein","year":"2010","journal-title":"J Nucl Cardiol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.nucmedbio.2006.10.002","article-title":"In vivo selective binding of (R)-[(11)C]rolipram to phosphodiesterase-4 provides the basis for studying intracellular cAMP signaling in the myocardium and other peripheral tissues","volume":"34","author":"M Kenk","year":"2007","journal-title":"Nucl Med Biol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1161\/01.HYP.25.4.796","article-title":"Angiotensin-(1\u20137) and nitric oxide interaction in renovascular hypertension","volume":"25","author":"H Nakamoto","year":"1995","journal-title":"Hypertension"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"F636","DOI":"10.1152\/ajprenal.2000.279.4.F636","article-title":"Differential actions of renal ischemic injury on the intrarenal angiotensin system","volume":"279","author":"AJ Allred","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"K Matsushita","year":"2010","journal-title":"Lancet"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ki.2010.536","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts","volume":"79","author":"M van der Velde","year":"2011","journal-title":"Kidney Int"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1007\/s00467-005-1982-x","article-title":"The role of calcium antagonists in patients with chronic renal failure","volume":"20","author":"KH Rahn","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1046\/j.1523-1755.1999.00614.x","article-title":"Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure","volume":"56","author":"M Noda","year":"1999","journal-title":"Kidney Int"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1440-1681.2010.05453.x","article-title":"Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5\/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?","volume":"37","author":"P Kujal","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/pr.59.3.3","article-title":"The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease","volume":"59","author":"H Kobori","year":"2007","journal-title":"Pharmacol Rev"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1152\/ajpcell.00287.2006","article-title":"Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system","volume":"292","author":"PK Mehta","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1146\/annurev.pharmtox.010909.105610","article-title":"Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy","volume":"50","author":"M Bader","year":"2010","journal-title":"Ann Rev Pharmacology Toxico"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s001090100210","article-title":"Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research","volume":"79","author":"M Bader","year":"2001","journal-title":"J Mol Med (Berl)"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1440-1681.2005.04181.x","article-title":"Differential regulation of angiotensin II receptors during renal injury and compensatory hypertrophy in the rat","volume":"32","author":"E Joly","year":"2005","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref54","first-page":"179","article-title":"Endothelin: a mediator of renal disease progression","volume":"10","author":"I Bruzzi","year":"1997","journal-title":"J Nephrol"},{"key":"ref55","first-page":"S63","article-title":"Nitric oxide\/endothelin balance after nephron reduction","volume":"65","author":"S Aiello","year":"1998","journal-title":"Kidney Int Suppl"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"RT Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/eurjhf\/hfq146","article-title":"The cardiac renin-angiotensin system is responsible for high-salt diet-induced left ventricular hypertrophy in mice","volume":"12","author":"P Le Corvoisier","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"80","author":"CA Herzog","year":"2011","journal-title":"Kidney Int"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jjcc.2010.09.004","article-title":"Chronic kidney disease and heart failure\u2014Bidirectional close link and common therapeutic goal","volume":"57","author":"N Shiba","year":"2011","journal-title":"J Cardiol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2220\/biomedres.32.83","article-title":"Left ventricular hypertrophy is associated with inflammation in sodium loaded subtotal nephrectomized rats","volume":"32","author":"Y Moriguchi","journal-title":"Biomed Res"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.HYP.0000049881.25304.73","article-title":"Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent","volume":"41","author":"KA Griffin","year":"2003","journal-title":"J Hypertens"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1172\/JCI118125","article-title":"Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys","volume":"96","author":"KA Griffin","year":"1995","journal-title":"J Clin Invest"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/ki.1983.72","article-title":"Hemodynamically mediated glomerular injury and the progressive nature of kidney disease","volume":"23","author":"BM Brenner","year":"1983","journal-title":"Kidney Int"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1152\/physrev.1999.79.2.387","article-title":"Signaling mechanisms underlying the vascular myogenic response","volume":"79","author":"MJ Davis","year":"1999","journal-title":"Physiol Rev"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.2215\/CJN.02231205","article-title":"Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade","volume":"1","author":"KA Griffin","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1046\/j.1523-1755.1999.00434.x","article-title":"Class differences in the effects of calcium channel blockers in the rat remnant kidney model","volume":"55","author":"KA Griffin","year":"1999","journal-title":"Kidney Int"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"F1136","DOI":"10.1152\/ajprenal.00401.2003","article-title":"Effects of calcium channel blockers on "dynamic" and "steady-state step" renal autoregulation","volume":"286","author":"KA Griffin","year":"2004","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0177451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:57:12Z","timestamp":1588967832000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0177451"}},"subtitle":[],"editor":[{"given":"Jaap A.","family":"Joles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,5,19]]},"references-count":67,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0177451","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,19]]}}}